Exemestane in the prevention setting

Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Cana...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2012-05, Vol.4 (3), p.107-112
Main Authors: Litton, Jennifer Keating, Bevers, Therese B., Arun, Banu K.
Format: Article
Language:English
Subjects:
Aromatase
Breast cancer
Clinical trials
Disease prevention
Mastectomy
Metastases
Reviews
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.
ISSN:1758-8340
1758-8359
1758-8359
DOI:10.1177/1758834012438214